Safety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: Study protocol for a randomized controlled trial

Trials

Volumn 16, Issue 1, 2015, Pages

  Rosso Fernández, Clara ^a   Montero, José Garnacho ^a   Antonelli, Massimo ^b   Dimopoulos, George ^c   Cisneros, José Miguel ^a   Gallmore, Paula Ramírez ^d   Bonastre, Juan ^d   González, Juan Carlos Montejo ^e   Díaz Miguel, Ramón Ortiz ^f   García, Angel Estella ^g   Crespo, Rafael Zaragoza ^h   Camerino, Rafael Sierra ⁱ   Gutiérrez, Manuel Herrera ^j   Alvarez Rocha, Luis ^k   Garcia, Miguel Sanchez ^l   Allegue Gallego, Jose M ^m   Ortega, álvaro Castellanos ⁿ   de la Torre Prados, María Victoria ^o   Roca, Ricard Ferrer ^p   Cortés, Pablo Vidal ^q   Armaganidis, Apostolos ^c   Nanas, Serafim ^r   Georgopoulos, Dimitrios ^s   Pneumatikos, Loannis ^t   Nakos, George ^u   Baltopoulos, George ^v   Koutsoukou, Antonia ^w   Zakynthinos, Epaminondas ^x   Papanikolaou, Militsa Bitsani ^y   Komnos, Apostolos ^z   Pennisi, Mariano ^b   Rocco, Monica ^aa   De Blasi, Roberto ^ab   De Gasperi, Andrea ^ac   Ranieri Francesco de Rosa, V Marco ^ad   De Robertis Rosalba, Edoardo ^ae   Guarracino, ^af   Fernández, Clara Rosso ^ag   Martínez, Fernando Pérez ^ag   de los Santos, María Perales ^ag   Monteau, Sophie ^ag   Gutierrez, Antonio ^ag   Milara, Caridad ^ag   Pachón, M Eugenia ^ag   Pulido, Marina ^ag   Moreno, Patricia ^ag   McConnell, Mike ^ag   Pérez, Fernando ^ag   López, Clementina ^ag   Cubiles, Laureano García ^ag   Martínez, Juliana ^ag   more..

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO DE CIUDAD REAL   (Spain)

^g HOSPITAL DE JEREZ   (Spain)

^h HOSPITAL UNIVERSITARIO DR PESET   (Spain)

ⁱ HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^j HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^k HOSPITAL JUAN CANALEJO   (Spain)

^l HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^m HOSPITAL GENERAL UNIVERSITARIO SANTA LUCÍA   (Spain)

ⁿ HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^o HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^p HOSPITAL MÚTUA DE TERRASSA   (Spain)

^q Unidad Clínica de Conductas Adictivas   (Spain)

^r EVANGELISMOS HOSPITAL   (Greece)

^s UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^t DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^u UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^v Oncology Hospital Ag Anargiri   (Greece)

^w SOTIRIA GENERAL HOSPITAL   (Greece)

^x UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^y Papanikolaou Hospital   (Greece)

^z GENERAL HOSPITAL OF LARISSA   (Greece)

^aa SAPIENZA UNIVERSITY OF ROME   (Italy)

^ab SAPIENZA UNIVERSITY OF ROME   (Italy)

^ac OSPEDALE NIGUARDA CA GRANDA   (Italy)

^ad MOLINETTE HOSPITAL   (Italy)

^ae UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^af AOU Cisanello   (Italy)

^ag Azienda Ospedaliera Sant'Andrea ^*

more..

Author keywords

Empirical therapy; Investigator driven; Multidrug resistant gram negative bacilli; Off label antibiotics resistance; Randomized controlled trial; Ventilator associated pneumonia

Indexed keywords

ACETAZOLAMIDE; ALLOPURINOL; COLISTIN; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; IMMUNOGLOBULIN; IODINATED CONTRAST MEDIUM; LEVOFLOXACIN; LINEZOLID; LITHIUM; MANNITOL; MEROPENEM; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARACETAMOL; PENICILLAMINE; RAPAMYCIN; TACROLIMUS; THIAZIDE DIURETIC AGENT; TOPIRAMATE; TORASEMIDE; TRIAMTERENE; VANCOMYCIN; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EUROPEAN; FEMALE; FOLLOW UP; GREECE; HOSPITALIZATION; HUMAN; INCIDENCE; INTENTION TO TREAT ANALYSIS; ITALY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PATENT; PHASE 4 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SEVERITY OF ILLNESS INDEX; SPAIN; THORAX RADIOGRAPHY; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA; YOUNG ADULT; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; EUROPE; GRAM-NEGATIVE BACTERIAL INFECTIONS; METHODOLOGY; MICROBIOLOGY; MULTIDRUG RESISTANCE; PNEUMONIA, VENTILATOR-ASSOCIATED; TIME FACTOR; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CLINICAL PROTOCOLS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EUROPE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INCIDENCE; PATENTS AS TOPIC; PNEUMONIA, VENTILATOR-ASSOCIATED; RESEARCH DESIGN; THIENAMYCINS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84925459705     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-015-0614-4     Document Type: Article

References (27)

1. Talbot GH, Bradley J, Edwards Jr JE, Gilbert D, Scheld M, Bartlett JG, et al. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis. 2006;42:657-68.
2. Pollack A. Rising threat of infections unfazed by antibiotics. The New York Times, February 26, 2010. http://www.nytimes.com/2010/02/27/business/27germ.html?_r=0.
3. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21:538-82.
4. Rodríguez-Baño J, Cisneros JM, Fernández-Cuenca F, Ribera A, Vila J, Pascual A, et al. Clinical features and epidemiology of Acinetobacter baumannii colonization and infection in Spanish hospitals. Infect Control Hosp Epidemiol. 2004;25:819-24.
5. Garnacho-Montero J, Ortiz-Leyba C, Fernandez-Hinojosa E, Aldabo-Pallas T, Cayuela A, Marquez-Vacaro JA, et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med. 2005;31:649-55.
6. Garnacho-Montero J, Sole-Violan J, Sa-Borges M, Diaz-Santos E, Rello J. Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: a matched cohort study. Crit Care Med. 2003;31:2478-82.
7. Reina R, Estenssoro E, Sáenz G, Canales HS, Gonzalvo R, Vidal G, et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med. 2005;31:1058-65.
8. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006;6(9):589-601.
9. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388-416.
10. Heyland DK, Dodek P, Muscedere J, Day A, Cook D, for the Canadian Critical Care Trials Group. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med. 2008;36:737-44.
11. Cisneros JM, Rodríguez-Baño J, Fernández-Cuenca F, Ribera A, Vila J, Pascual A, et al. Risk factors for the acquisition of imipenem-resistant Acinetobacter baumannii in Spain: a nationwide study. Clin Microbiol Infect. 2005;11:874-9.
12. Olaechea PM, Insausti J, Blanco A, Luque P. Epidemiologia de las infecciones nosocomiales. Med Intensiva. 2010;34:256-67. Spanish.
13. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infec Dis. 2005;40:1333-41.
14. Montero A, Ariza J, Corbella X, Doménech A, Cabellos C, Ayats J, et al. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother. 2004;54:1085-91.
15. Pachon-Ibanez ME, Fernandez-Cuenca F, Docobo-Perez F, Pachón J, Pascual A. Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam. J Antimicrob Chemother. 2006;58:689-92.
16. Falagas ME, Rafailidis PI, Ioannidou E, Alexiou VG, Matthaiou DK, Karageorgopoulos DE, et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents. 2010;35:194-9.
17. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, Barrero-Almodovar AE, Garcia-Garmendia JL, Bernabeu-Wittell M, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis. 2003;36:1111-8.
18. Kallel H, Hergafi L, Bahloul M, Hakim A, Dammak H, Chelly H, et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med. 2007;33:1162-7.
19. Paul M, Bishara J, Levcovich A. Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother. 2010;65:1019-27.
20. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother. 2009;53:3430-6.
21. Bassetti M, Repetto E, Righi E, Boni S, Diverio M, Molinari MP, et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother. 2008;61:417-20.
22. Aydemir H, Akduman D, Piskin N, Comert F, Horuz E, Terzi A, et al. Colistine versus the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator associated pneumonia. Epidemiol Infect. 2013;141:1214-22.
23. Durante-Mangioni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013;57(3):349-58.
24. Magic Bullet. Seventh framework program for research and development (Grant Agreement 278232). http://www.magicbullet7fp.eu/. Accessed March 12th 2015.
25. Fletcher B, Gheorghe A, Moore D, Wilson S, Damery S. Improving the recruitment activity of clinicians in randomised controlled trials: a systematic review. BMJ Open. 2012;2:e000496.
26. Innovative Medicines Initiative. New drugs for bad bugs. http://www.imi.europa.eu/content/nd4bb. Accessed March 3th, 2015.
27. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med. 2008;36(4):1089-96.